Corbus Pharmaceuticals (CRBP) AI Stock Analysis

• Market Cap: $158.56M
• Dividend Yield: N/A
• Average Volume (3M): 503.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: N/A
• EPS Growth: -17.43%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.25
• Shares Outstanding: 17,736,464
• 10 Day Avg. Volume: 744,820
• 30 Day Avg. Volume: 503,638
• PEG Ratio: -0.02
• Price to Book (P/B): 0.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.68
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -5.34
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $41.27
• Price Target Upside: 361.63% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -4.93
• Revenue Forecast (FY): $5.33M

• Rating: 57 Neutral
• Price Target: $10.00 ▲(11.86% Upside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

The score is driven by a stronger balance sheet and positive corporate updates (including extended runway into 2028), partly offset by a pre-revenue model with widening losses and increasing cash burn. Technicals add modest support due to improving near-term momentum, while negative earnings (negative P/E) weighs on valuation.

Positive Factors

Balance sheet strength

Returning to positive equity and carrying minimal debt provides durable financial flexibility. This capital structure supports multi-year R&D investment, reduces near-term refinancing risk, and enables options like partnerships or milestone-based deals to fund programs without immediate reliance on dilutive financings.

Extended cash runway

A meaningful equity raise that materially increased cash balances and extended runway into 2028 lowers near-term funding pressure. This allows management to advance mid- and late-2026 clinical programs and regulatory planning without urgent capital raises, supporting execution of value-driving milestones.

Diversified, advancing pipeline

Progress on CRB-701 (Nectin-4 ADC) and CRB-913 (oral obesity agent) gives Corbus two distinct franchises with differentiated mechanisms and early safety/efficacy signals. Successful mid- and late-2026 readouts could validate clinical differentiation and create multiple long-term commercialization pathways.

Negative Factors

Pre-revenue with widening losses

The company remains pre-commercial and reported materially wider net losses in 2025 driven by R&D and operating spend. Without product revenues, persistent losses can erode equity over time, increase reliance on external capital, and constrain strategic flexibility absent successful trial outcomes.

Rising cash burn

Operating cash flow deterioration demonstrates accelerating burn as clinical programs scale. Sustained negative cash conversion increases funding dependence; even with current runway, unexpected trial extensions, higher enrollment costs, or program expansions could necessitate additional financing or dilute shareholders.

Binary clinical and regulatory risk

Value is highly contingent on upcoming clinical readouts and regulatory design feedback. Negative or inconclusive data or unfavorable registrational guidance would materially impair commercial prospects and valuation trajectory, since the company lacks revenues and late-stage backups to offset clinical failures.

Corbus Pharmaceuticals Business Overview & Revenue Model

Company Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

How the Company Makes Money

null

Corbus Pharmaceuticals Financial Statement Overview

Summary

Financial profile is mixed: the balance sheet is a clear strength with positive equity (~$147.5M in 2025) and very low debt (~$1.6M), but the business remains pre-revenue with widening losses (net income -$78.5M in 2025) and rising cash burn (operating cash flow about -$64.5M in 2025).

Income Statement

CRBP remains a pre-commercial biotech with essentially no revenue in 2022–2025 (and only ~$0.9M in 2021 and ~$3.9M in 2020), so results are dominated by operating expenses. Losses persist each year, with net income deteriorating to -$78.5M in 2025 from -$40.2M in 2024, indicating a higher cash burn profile. Profitability is structurally weak with consistently negative operating results, and the lack of a revenue base limits near-term margin improvement visibility.

Balance Sheet

The balance sheet improved meaningfully versus 2023 when equity was negative (suggesting prior balance sheet stress), returning to positive equity of ~$142.4M in 2024 and ~$147.5M in 2025. Leverage is currently very low, with total debt down to ~$1.6M in 2025 and a modest debt-to-equity ratio (~0.01), which provides financial flexibility. The key weakness is ongoing losses driving a negative return on equity (about -53% in 2025), which could erode the equity base over time if the company continues to fund operations without a revenue ramp.

Cash Flow

Cash generation remains the central challenge: operating cash flow and free cash flow are negative every year shown, with 2025 operating cash flow at about -$64.5M (worse than -$41.8M in 2024). While free cash flow growth is positive in 2025, it reflects a larger negative outflow rather than a move toward breakeven. A relative positive is that cash flow and net losses are closely aligned (free cash flow roughly tracks net income), but the direction of burn in 2025 increases funding risk if sustained.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	881.71K
Gross Profit	-233.00K	-600.00K	0.00	-1.49M	-757.53K
EBITDA	-85.08M	-37.74M	-40.10M	-38.73M	-54.35M
Net Income	-78.54M	-40.21M	-44.60M	-55.83M	-45.55M
Balance Sheet
Total Assets	168.19M	155.88M	28.27M	66.31M	107.73M
Cash, Cash Equivalents and Short-Term Investments	28.49M	149.06M	20.91M	59.20M	97.65M
Total Debt	1.63M	3.24M	20.89M	25.09M	26.59M
Total Liabilities	20.69M	13.45M	35.18M	33.32M	38.62M
Stockholders Equity	147.50M	142.43M	-6.91M	32.99M	69.11M
Cash Flow
Free Cash Flow	-64.50M	-41.79M	-36.10M	-37.56M	-48.24M
Operating Cash Flow	-64.49M	-41.79M	-36.10M	-37.54M	-48.18M
Investing Cash Flow	-1.64M	-121.31M	35.64M	30.07M	-73.42M
Financing Cash Flow	77.43M	166.58M	-2.82M	-533.62K	60.82M

Corbus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.94
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBP, the sentiment is Negative. The current price of 8.94 is above the 20-day moving average (MA) of 8.71, above the 50-day MA of 8.41, and below the 200-day MA of 10.02, indicating a neutral trend. The MACD of 0.33 indicates Negative momentum. The RSI at 51.89 is Neutral, neither overbought nor oversold. The STOCH value of 50.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBP.

Corbus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRBP	57 Neutral	$158.56M	-1.38	-65.76%	―	―	-17.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BMEA	50 Neutral	$77.07M	-1.25	-209.00%	―	―	40.22%
TCRX	49 Neutral	$59.18M	-1.00	-71.28%	―	-10.03%	11.06%
ATOS	43 Neutral	$44.18M	-3.22	-49.42%	―	―	-9.42%

Corbus Pharmaceuticals Corporate Events

Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress

On March 9, 2026, Corbus Pharmaceuticals reported fourth-quarter and full-year 2025 results, highlighting strong clinical progress across its pipeline and a bolstered balance sheet. In oncology, Q4 2025 Phase 1/2 data for CRB-701 in head and neck squamous cell carcinoma, cervical cancer and bladder cancer showed encouraging unconfirmed response rates and favorable safety, with 2026 catalysts including FDA feedback on registrational study designs, mid-2026 monotherapy durability data, and late-2026 Keytruda combination data in first-line HNSCC.

In obesity, Corbus reported December 2025 Phase 1a SAD/MAD data for CRB-913 showing a 2.9% placebo-adjusted 14-day weight loss with a favorable gastrointestinal and neuropsychiatric profile, and it expects to complete a 12-week, 240-patient Phase 1b study in summer 2026. The company also completed a Phase 1 trial of CRB-601 but has deprioritized the program, and despite a wider quarterly net loss driven by higher clinical spending, a $75 million Q4 2025 equity offering lifted cash and investments to $163.3 million at year-end, extending the operating runway into 2028 and reinforcing Corbus’s ability to advance its lead assets in a competitive oncology and obesity landscape.

The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Corbus Highlights Diversified Oncology and Metabolic Pipeline Outlook

Corbus Pharmaceuticals presented an updated corporate overview dated February 25, 2026, highlighting a diversified pipeline led by CRB-701, a next-generation Nectin-4–targeting ADC designed for longer half-life, reduced free MMAE exposure, fewer PADCEV-associated toxicities, and a best-in-class dosing regimen, with ongoing studies in head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial carcinoma across the U.S. and Europe. The company also underscored upcoming 2026 milestones, including 12-week dose-range finding data for CRB-913 in obesity, dose-escalation data for CRB-601 in αvβ8-enriched solid tumors, and emerging ESMO 2025 data showing a favorable safety profile for CRB-701 versus Nectin-4–MMAE peers, supported by a cash position of $173 million as of November 3, 2025, and a relatively low share count, which collectively reinforce its financial capacity and strategic positioning in competitive oncology and metabolic disease markets.

The most recent analyst rating on (CRBP) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Corbus Updates Corporate Outlook, Highlights Diversified 2026 Pipeline

On January 12, 2026, Corbus Pharmaceuticals updated its corporate presentation to highlight a diversified pipeline and key clinical milestones expected in 2026, underpinned by $173 million in cash, cash equivalents and investments as of November 3, 2025 and a relatively low share count of about 17.6 million common shares outstanding. The materials emphasize CRB-701 as a potentially best-in-class Nectin-4 antibody-drug conjugate with a proprietary design that delivers longer half-life, lower free MMAE exposure and a more convenient dosing regimen than current Nectin-4/MMAE competitors, alongside emerging safety data from a 167-patient dataset presented at ESMO 2025 showing lower rates of high-grade adverse events and peripheral neuropathy versus peer agents, positioning the drug to target high Nectin-4–expressing tumors such as head and neck, cervical and urothelial cancers. Corbus also outlines a 12-week, 240-patient mid-2026 obesity readout for CRB-913 and dose-escalation progress for CRB-601 in αvβ8-enriched solid tumors, signaling an active clinical year that could be pivotal for validating its oncology and metabolic franchises and strengthening its competitive standing in the ADC and obesity drug markets.

The most recent analyst rating on (CRBP) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Corbus Pharmaceuticals Announces Retirement of Board Member Holmer

On December 12, 2025, Corbus Pharmaceuticals Holdings, Inc. announced that board member Alan Holmer notified the company of his decision to retire and will resign from its Board of Directors effective December 31, 2025. The company stated that Holmer’s departure was not due to any disagreement over its operations, policies, or practices, suggesting an orderly governance transition with no underlying operational or strategic dispute signaled to stakeholders.

The most recent analyst rating on (CRBP) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Corbus Pharmaceuticals Advances Obesity Treatment with CRB-913

On December 11, 2025, Corbus Pharmaceuticals announced the completion of its Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity management, and the initiation of a Phase 1b study expected to conclude in summer 2026. The Phase 1a study demonstrated that CRB-913 was safe, well-tolerated, and effective in promoting weight loss, with no serious adverse events reported, marking a significant step forward in Corbus’ obesity treatment research.

The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.